New study below [1].
The MMP (matrix metalloproteinase / metallopeptidase) family break down the matrix that holds cells in place. MMPs are elevated in cancer & facilitate metastasis.
If this were only another cell study I might have hesitated to post. But:
"PC3‐Luc cells were injected into SCID mouse prostates .... We found that three times weekly administration of melatonin (20–60 mg/kg) concentration‐dependently inhibited prostate cancer development ... Importantly, melatonin suppressed the metastasis of prostate cancer to distant organs, including the lung, liver, and bone ... To validate the molecular target in melatonin‐treated cells, we conducted an IHC analysis of prostate tumor specimens. The results revealed that melatonin markedly inhibited the expression of MMP‐13 ... Hematoxylineosin staining confirmed that melatonin markedly reduced the metastasis of prostate cancer to the lung, liver, and bone ... Based on these findings, we propose that melatonin impedes in vivo metastasis by suppressing MMP‐13 expression in human prostate cancer."
OK, so you are looking at that 20–60 mg/kg dosage, rapidly converting lbs to kgs & coming up with an impossible dose, but the result is intriguing.
-Patrick
[1] pubmed.ncbi.nlm.nih.gov/332...
J Cell Physiol
. 2020 Nov 29. doi: 10.1002/jcp.30150. Online ahead of print.
Melatonin impedes prostate cancer metastasis by suppressing MMP-13 expression
Shih-Wei Wang 1 2 , Huai-Ching Tai 3 4 , Chih-Hsin Tang 5 6 7 , Liang-Wei Lin 1 5 , Tien-Huang Lin 8 9 , An-Chen Chang 5 , Po-Chun Chen 10 , Yi-Hsuan Chen 1 11 , Po-Chuan Wang 12 , Yu-Wei Lai 13 14 , Shiou-Sheng Chen 14 15 16
Affiliations collapse
Affiliations
1 Department of Medicine, MacKay Medical College, New Taipei City, Taiwan.
2 Graduate Institute of Natural Products, College of Pharmacy, Kaohsiung Medical University, Kaohsiung, Taiwan.
3 School of Medicine, Fu-Jen Catholic University, New Taipei City, Taiwan.
4 Department of Urology, Fu-Jen Catholic University Hospital, New Taipei City, Taiwan.
5 Department of Pharmacology, School of Medicine, China Medical University, Taichung, Taiwan.
6 Chinese Medicine Research Center, China Medical University, Taichung, Taiwan.
7 Department of Biotechnology, College of Health Science, Asia University, Taichung, Taiwan.
8 Department of Urology, Buddhist Tzu Chi General Hospital Taichung Branch, Taichung, Taiwan.
9 School of Post-Baccalaureate Chinese Medicine, Tzu Chi University, Hualien, Taiwan.
10 Central Laboratory, Shin-Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
11 Department of Urology, MacKay Memorial Hospital, Taipei, Taiwan.
12 Department of Gastroenterology, Hsinchu MacKay Memorial Hospital, Hsinchu City, Taiwan.
13 Division of Urology, Taipei City Hospital Renai Branch, Taipei, Taiwan.
14 Department of Urology, National Yang-Ming University School of Medicine, Taipei, Taiwan.
15 Division of Urology, Taipei City Hospital Zhongxiao Branch, Taipei, Taiwan.
16 Commission for General Education, College of Applied Science, National Taiwan University of Science and Technology, Taipei, Taiwan.
PMID: 33251599 DOI: 10.1002/jcp.30150
Abstract
Prostate cancer has high metastatic potential. Men with higher urinary levels of the sleep hormone melatonin are much less likely to develop advanced prostate cancer compared with men with lower levels of melatonin. Melatonin has shown anticancer activity in experimental investigations. Nevertheless, the therapeutic effect of melatonin in metastatic prostate cancer has largely remained a mystery. Analyses of Gene Expression Omnibus data and human tissue samples indicated that levels of matrix metallopeptidase 13 (MMP-13) expression are higher in prostate cancer patients than in healthy cancer-free individuals. Mechanistic investigations revealed that melatonin inhibits MMP-13 expression and the migratory and invasive capacities of prostate cancer cells via the MT1 receptor and the phospholipase C, p38, and c-Jun signaling cascades. Importantly, tumor growth rate and metastasis to distant organs were suppressed by melatonin in an orthotopic prostate cancer model. This is the first demonstration showing that melatonin impedes metastasis of prostate cancer by suppressing MMP-13 expression in both in vitro and in vivo models. Thus, melatonin is promising in the management of prostate cancer metastasis and deserves to undergo clinical investigations.
Keywords: MMP-13; MT1 receptor; melatonin; metastasis; prostate cancer.
© 2020 Wiley Periodicals LLC.